Secondary Metabolites Isolated From <i>Streptomyces</i> sp. MJM3055 and Their Cytotoxicity Against Jurkat Cells

Qiu, Yinda; Yoo, Hee Min; Cho, Namki; Yan, Pengcheng; Liu, Zhiguo; Cheng, Jinhua; Suh, Joo‐Won

doi:10.1177/1934578x20977591

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To get insight about the receptor-based pharmacophore model generation for PIK3CA-inhibitor complex, experimentally resolved structure (4JPS) was retrieved from the PDB [ 28 ]. The structure of PIK3CA was generated by removing the heteroatoms.…”

Section: Methodsmentioning

confidence: 99%

[Retracted] Targeting Streptomyces‐Derived Streptenol Derivatives against Gynecological Cancer Target PIK3CA: An In Silico Approach

Christy

Vasudevan

Sudha

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Streptomyces is amongst the most amenable genera for biotechnological applications, and it is extensively used as a scaffold for drug development. One of the most effective therapeutic applications in the treatment of cancer is targeted therapy. Small molecule therapy is one of them, and it has gotten a lot of attention recently. Streptomyces derived compounds namely streptenols A, C, and F–I and streptazolin were subjected for ADMET property assessment. Our computational studies based on molecular docking effectively displayed the synergistic effect of streptomyces-derived compounds on the gynecological cancer target PIK3CA. These compounds were observed with the highest docking scores as well as promising intermolecular interaction stability throughout the molecular dynamic simulation. Molecular docking and molecular dynamic modeling techniques were utilized to investigate the binding mode stability of drugs using a pharmacophore scaffold, as well as physicochemical and pharmacokinetic aspects linked to alpelisib. With a root mean square fluctuation of the protein backbone of less than 0.7 nm, they demonstrated a steady binding mode in the target binding pocket. They have also prompted hydrogen bonding throughout the simulations, implying that the chemicals have firmly occupied the active site. A comprehensive study showed that streptenol D, streptenol E, streptenol C, streptenol G, streptenol F, and streptenol B can be considered as lead compounds for PIK3CA-based inhibitor design. To warrant the treatment efficacy against cancer, comprehensive computational research based on proposed chemicals must be assessed through in vitro studies.

show abstract

Section: Methodsmentioning

confidence: 99%

[Retracted] Targeting Streptomyces‐Derived Streptenol Derivatives against Gynecological Cancer Target PIK3CA: An In Silico Approach

Christy

Vasudevan

Sudha

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The antitumoral compounds found in Streptomyces are promising agents for the clinical treatment of malignant cell growth or tumors 76 . These compounds can belong to different chemical classes, including polyketides, 77 streptenols, 78 exopolysaccharides, 79 peptides, 80 diketopiperazines 81 , and others 82 . The treatment of cancer using synthetic drugs causes adverse side effects, including vomiting, nausea, and varied types of pain.…”

Section: Streptomyces Genusmentioning

confidence: 99%

Genus Streptomyces: Recent advances for biotechnological purposes

Júnior

Sousa²,

Oliveira

et al. 2023

Biotech and App Biochem

View full text Add to dashboard Cite

Actinomycetes are a distinct group of filamentous bacteria. The Streptomyces genus within this group has been extensively studied over the years, with substantial contributions to society and science. This genus is known for its antimicrobial production, as well as antitumor, biopesticide, and immunomodulatory properties. Therefore, the extraordinary plasticity of the Streptomyces genus has inspired new research techniques. The newest way of exploring Streptomyces has comprised the discovery of new natural metabolites and the application of emerging tools such as CRISPR technology in drug discovery. In this narrative review, we explore relevant published literature concerning the ongoing novelties of the Streptomyces genus.

show abstract

“…CA-271078: one each of types A (28) and C (31), and two of which were type B napyradiomycins (29 and From a group of six compounds isolated from Streptomyces sp. MJM3055 and spectroscopically characterised, two compounds, (3E,8E)-1-hydroxydeca-3,8-dien-5-one ( 24) and (S,E)-3-hydroxy-5-oxodec-8-en-1-yl acetate (25), were identified as novel natural products via a Jurkat cell antiproliferation screening study (Figure 9) [20]. Using LCMSguided screening of Streptomyces sp.…”

Section: Terpenoidsmentioning

confidence: 99%

Recently Discovered Secondary Metabolites from Streptomyces Species

Lacey

Rutledge

2022

Molecules

View full text Add to dashboard Cite

The Streptomyces genus has been a rich source of bioactive natural products, medicinal chemicals, and novel drug leads for three-quarters of a century. Yet studies suggest that the genus is capable of making some 150,000 more bioactive compounds than all Streptomyces secondary metabolites reported to date. Researchers around the world continue to explore this enormous potential using a range of strategies including modification of culture conditions, bioinformatics and genome mining, heterologous expression, and other approaches to cryptic biosynthetic gene cluster activation. Our survey of the recent literature, with a particular focus on the year 2020, brings together more than 70 novel secondary metabolites from Streptomyces species, which are discussed in this review. This diverse array includes cyclic and linear peptides, peptide derivatives, polyketides, terpenoids, polyaromatics, macrocycles, and furans, the isolation, chemical structures, and bioactivity of which are appraised. The discovery of these many different compounds demonstrates the continued potential of Streptomyces as a source of new and interesting natural products and contributes further important pieces to the mostly unfinished puzzle of Earth’s myriad microbes and their multifaceted chemical output.

show abstract

Secondary Metabolites Isolated From Streptomyces sp. MJM3055 and Their Cytotoxicity Against Jurkat Cells

Cited by 3 publications

References 24 publications

[Retracted] Targeting Streptomyces‐Derived Streptenol Derivatives against Gynecological Cancer Target PIK3CA: An In Silico Approach

[Retracted] Targeting Streptomyces‐Derived Streptenol Derivatives against Gynecological Cancer Target PIK3CA: An In Silico Approach

Genus Streptomyces: Recent advances for biotechnological purposes

Recently Discovered Secondary Metabolites from Streptomyces Species

Contact Info

Product

Resources

About